Literature DB >> 7173304

Pharmacokinetics and tolerance of slow-release indomethacin tablets in rheumatoid arthritis.

K Kaarela, K Lehtinen, P Mäkisara, K Holttinen, U Lamminsivu, A Gordin.   

Abstract

The pharmacokinetics, efficacy and tolerance of a new formulation of slow-release indomethacin tablet were compared with those of a conventional indomethacin capsule in 30 patients with rheumatoid arthritis. The slow-release tablet was absorbed more slowly than the capsule (tmax 3.7 h and less than 2 h, respectively) and produced more even serum drug levels in 10 subjects. Side-effects, especially dizziness and diarrhoea, were less frequent after the slow-release tablet than during the capsule period.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7173304     DOI： 10.1007/bf00613619

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  6 in total

1.  [Bioavailability of indomethacin. Study of a delayed-action preparation].

Authors:  E Vignon; M C Chapuy
Journal:  Rev Rhum Mal Osteoartic       Date:  1979 Jul-Sep

2.  A comparison of the pharmacokinetics of piroxicam with those of plain and slow release indomethacin. A crossover study.

Authors:  M Schoog; H Laufen; P Dessain
Journal:  Eur J Rheumatol Inflamm       Date:  1981

3.  Sustained release indomethacin: a double blind comparison with indomethacin suppositories.

Authors:  O Iversen; M Fowles; M Vlieg; N Smidt; R Wigley
Journal:  N Z Med J       Date:  1981-04-22

4.  Clinical Pharmacokinetics of indomethacin.

Authors:  L Helleberg
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

5.  Indomethacin in rheumatoid arthritis: clinical effects, pharmacokinetics, and platelet studies in responders and nonresponders.

Authors:  N Baber; L D Halliday; W J van den Heuvel; R W Walker; R Sibeon; J P Keenan; T Littler; M L Orme
Journal:  Ann Rheum Dis       Date:  1979-04       Impact factor: 19.103

6.  [Clinico-pharmacological investigation of an oral form of a depot preparation on silicone resin base with indomethacin as the active ingredient].

Authors:  J Metzner; H Bekemeier; H Kala; P Hanke; W Schmollack
Journal:  Z Gesamte Inn Med       Date:  1980-05-01
  6 in total
  5 in total

1.  A six-month follow-up study of a slow-release indomethacin tablet in rheumatic diseases.

Authors:  K Lehtinen; K Kaarela; M Ahonen; S Forsberg; R Luukkainen; J Martio; O Mutru; E Nykänen; P Nykänen; J Pesonen
Journal:  Clin Rheumatol       Date:  1987-12       Impact factor: 2.980

Review 2.  Novel oral drug formulations. Their potential in modulating adverse effects.

Authors:  A T Florence; P U Jani
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

3.  Chronopharmacokinetic study of a prolonged release form of indomethacin.

Authors:  P Guissou; G Cuisinaud; G Llorca; E Lejeune; J Sassard
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  The safety profile of sustained-release etodolac.

Authors:  M Schattenkirchner
Journal:  Rheumatol Int       Date:  1993       Impact factor: 2.631

Review 5.  Application of liposomes in treatment of rheumatoid arthritis: quo vadis.

Authors:  Bhupinder Kapoor; Sachin Kumar Singh; Monica Gulati; Reena Gupta; Yogyata Vaidya
Journal:  ScientificWorldJournal       Date:  2014-02-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.